Biomarker Platform Articles & Analysis
27 news found
The project is leveraging the fully integrated BioMark’s metabolomic liquid biopsy platform to develop a safe, effective, and affordable drug biomarker test to assess and monitor response to therapy which could provide both clinician and patient with an accurate and easy way to perform relapse surveillance and therapeutic monitoring more ...
“I am thrilled to be joining Bodyport, to work alongside such a passionate, mission-driven, and innovative team to bring our platform to heart disease patients and their clinical teams,” said Amit Rushi. “Bodyport is pioneering an incredibly intuitive care management platform to make a meaningful difference in the quality of care for ...
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors. ...
Business Update Highlights “Our Q2 results demonstrate BioMark’s continued efforts to advance our technology platform with exceptional clinical data, expand our global partnerships, and accelerating the commercialization of its early lung cancer blood-based assay despite a challenging macro environment” said CEO Rashid Bux. ...
The multicenter trial will also enable deep clinical and biological data collection to strengthen STALICLA’s platform. Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced ...
BySTALICLA
STALICLA's unique approach addresses a major weakness in the drug development process for NDDs and neuropsychiatric disorders: behaviour is a terrible biomarker. Thanks to DEPI, a proprietary platform aggregating molecular data and human genetic information, STALICLA pushes the frontier of precision medicine further into precision NDDs. ...
BySTALICLA
Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug Administration (FDA) 510(k) clearance. ...
John Lipman: We plan on developing new biomarkers and algorithms that help better predict worsening status in patients living with complex chronic conditions. New biomarkers and algorithms will enable us to detect adverse events earlier and more precisely, further enhancing our ability to keep patients out of the hospital and in their homes. ...
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, today announced the appointment of medtech industry veteran, John Lipman, as Chief Executive Officer. ...
The Alzheimer's Podcast is available on all major podcast platforms including Apple Podcasts, Google Podcasts, Amazon Music and Spotify, as well as HealthUnmuted.com. ...
Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize its AI-driven digital biomarker platform. She will report directly to the Chief Executive Officer of Altoida, Travis Bond, and will serve on the Leadership team. ...
BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. ...
PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter’s new Clinical ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI ...
Recently, the company announced the launch of biomarker and target discovery service for disease identification, early diagnosis and prevention, and monitoring during treatment. ...
For example, through gene microarrays, genes that may be affected by diseases can be discovered in a short time as biomarkers for early diagnosis. "The platform has a skilled bioinformatics analysis team with extensive experience in biological data analysis projects. ...
Martin Rottman, Professor of Clinical Microbiology at Université de VersaillesSt Quentin and Director of the Innovative Biomarkers Platform at Assistance Publique - Hôpitaux de Paris, France, was carried out at Hôpital Raymond Poincaré. ...
“By eliminating the need for acquiring additional data, 4D Path’s patented methods and integrated platform accelerate complete, actionable and proven clinical insights that are completely objective. ...
FDA submissions for regulatory approvals will run in parallel, with the project concluding in a virtual clinical study on participants opting-in to test and validate the entire platform. The tested hardware will consist of EmbracePlus, a medical device in a smartwatch form-factor, with clinical-grade sensors that measure heart rate, heart rate variability, temperature, ...